{
  "docId": "019de072-ece7-71de-8eba-0df52639d987",
  "docSlug": "f4caf3b83872d8591c78c133c07757ed",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 19 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 19,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a process diagram to show the transition from Part A to Part B.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-ece7-71de-8eba-0df52639d987/12",
  "deckHref": "/decks/019de072-ece7-71de-8eba-0df52639d987",
  "deckJsonHref": "/decks/019de072-ece7-71de-8eba-0df52639d987.json",
  "deckAnchorHref": "/decks/019de072-ece7-71de-8eba-0df52639d987#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Our intention is to out-licence development and commercialisation of BEN-2293 following completion of this trial, with key Big Pharma and Dermatology specialists as potential partners",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4750acab-69f4-42ff-8fdb-c228767f2792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.27
      },
      "kind": "diagram",
      "text": "Part A (1, 2, 3, 4) -> Part B",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c277ff1-fe35-4995-9e98-a1ec212fc90c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.65,
        "y": 0.38
      },
      "kind": "list",
      "text": "Part B: Efficacy Cohort(s). Full data expected end of 2022. 45 Mild-Moderate AD patients per arm. Efficacy endpoints include itch (NRS), inflammation (vIGA, EASI), and biomarker panel.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "159b9a14-559c-4e8d-bc14-4da7eefb199a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "Part A: First in Human Dose Escalation. Completed Dec 2021. 8 Mild-Moderate AD patients per cohort, randomised 3:1. Safety, Tolerability, PK.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26898499-6fa0-4ea2-9585-cc9b931939d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "SRC: Safety Review Committee",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15228c11-effa-4ef5-b4dc-bb1f0d14f55b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "BEN-2293 is progressing in an adaptive Phase I/II clinical study, with full data expected end of 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9977bebf-e799-4a8d-8b53-d805d4b37dbe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "fc73ab0e-6ab6-4c4c-be19-4db19f14ebbc",
      "evidence": "The slide uses a sequential arrow diagram to represent clinical trial phases.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "b60aafe0-945b-4485-b373-af4183f36f2b",
      "evidence": "BEN-2293 and BEN-8744 progress",
      "position": 1,
      "objective": "Showcase quick wins and big bets in pipeline",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}